Alzheimer’s drug slows disease in breakthrough trial
Biogen Inc. and partner Eisai Co said their experimental drug lecanemab significantly slowed the disease, making it the first medicine to blunt progression of the most common dementia in a large definitive study
citynews
8
Biogen Inc. and partner Eisai Co said their experimental drug lecanemab significantly slowed the disease, making it the first medicine to blunt progression of the most common dementia in a large definitive study
